Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage biopharmaceutical company focused on in-licensing, developing and commercializing oncology drug candidates in China, US, and the rest of the world.

Xynomic Pharmaceuticals Holdings, Inc.

IPhone / Mobile Compatible

Viewport Meta

Apple Mobile Web Clips Icon

Google Font API

WordPress

Font Awesome

Microsoft Exchange Online

Apache

Office 365 Mail

Chairman, CEO & President

Mark Xu

Chief Development Officer and Executive VP Quality

Sophia Paspal

Jason Wu

Co-founder, Chairman, CEO & President

China Early Stage Companies With Less Than $1B in Revenue

Asia Startups Founded in 2016

Asia Biotechnology Companies with Early Stage Venture Funding

Biotechnology Startups

Xynomic Pharma focuses on in-licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. The founding executives worked at leading multinational biopharmaceutical companies (Schering, Eli Lilly, Merck, and Roche) in R&D roles. The founders also had successful entrepreneurial experiences including founding, building, and exiting successful US-China biopharmaceutical companies.Xynomic Pharma aims to build a comprehensive clinical and pre-clinical stage oncology pipeline targeting cancers with high prevalence in China, US and rest of the world.  Xynomic Pharma leverages global resources, enabling the company to develop drugs in a cost and time-efficient manner.

Hakim Unique Internet

Northern Light Venture Capital

Zhongshan Bison Healthcare Investment

Series B - Xynomic Pharmaceuticals

Series A - Xynomic Pharmaceuticals

Seed Round - Xynomic Pharmaceuticals

Shanghai

China

Asia

Xynomic Pharmaceuticals

HDAC Inhibitor Clinical Trial Pipeline Appears Robust With 25 ...

Hematopoietic Stem Cell Transplantation Market to Grow ...

Propulsion of Small Lymphocytic Lymphoma Clinical Trial ...

The renal cell carcinoma drug market

Diffuse Large B-cell Lymphoma Market to Show Immense ...

Focuses on acquiring, developing, and bringing to market oncology drugs in China, US, and globally.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Sep 16, 2024 1:53 PM	2f2944f0
public peers	general	Sep 16, 2024 9:44 AM	735b8c81
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 16, 2024 10:21 AM	2f40d7f6
company summary	general
signals	general	Sep 16, 2024 9:44 AM	44fbab8c
crunchbase trigger	general	Nov 27, 2024 12:50 PM	e62e1644
crunchbase profile	general	Nov 27, 2024 6:06 PM	dcb36e30
li profile	general
translate crunchbase fundingrounds	general	Nov 27, 2024 7:32 PM	5a99a49f
peers	general	Sep 16, 2024 9:44 AM	d85e9bb6
news basic	general	Sep 16, 2024 9:44 AM	d7a20589
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:XYNOMICPHARMA

Xynomic Pharmaceuticals Holdings, Inc.